The 2026 LiBBY trial found that a low-dose THC/CBD combination significantly reduced agitation in people with advanced dementia, but it also produced nearly twice the rate of serious adverse events seen with placebo. That gap is the central safety question researchers still have to resolve before this drug reaches anyone outside a trial, and it says nothing about whether the approach is safe for adults with milder memory problems.
LiBBY (Lowering Agitation with Cannabinoids in Alzheimer's/Dementia at End of Life) was a Phase 2, placebo-controlled study of an oral formulation called T2:C100 — 2 mg of THC paired with 100 mg of CBD — tested in 120 hospice-eligible adults with advanced dementia across roughly ten U.S. sites, sponsored by the National Institute on Aging rather than a pharmaceutical company, according to Georgetown University Medical Center. What it showed, and what it left unanswered, matters for anyone following cannabinoid research in dementia care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the Trial Actually Tested and Found
- The Safety Signal Researchers Still Need to Explain
- What's Missing Before Any Conclusions Are Final
- Does This Apply to Earlier-Stage Memory Concerns?
- What Caregivers and Clinicians Should Do Now
- Frequently Asked Questions
What the Trial Actually Tested and Found
LiBBY enrolled people already eligible for hospice care who had clinically significant agitation tied to advanced dementia — not people in early-stage memory decline. Participants received either the T2:C100 oral drug or a placebo, and researchers tracked agitation using the Cohen-Mansfield Agitation Inventory (CMAI), a standard clinical scale for rating behaviors like restlessness, aggression, and resistance to care.
Topline results presented at the Alzheimer's Association International Conference (AAIC) in London reported that the trial met its primary endpoint: agitation scores dropped significantly more in the treatment group at two weeks, and that improvement held through the twelve-week study period, according to the AAIC/Alzheimer's Association. By week twelve, the treated group's CMAI score had fallen 8.23 points more than the placebo group's, and roughly 84% of people on the drug showed improvement at two weeks compared with about 31% on placebo, per conference coverage reported by NeurologyLive.
The Safety Signal Researchers Still Need to Explain
The adverse event numbers are where the trial gets complicated. Overall adverse events were close between groups — 46.7% in the treatment arm versus 42.4% on placebo — but serious adverse events were roughly double in the treatment group, at 23.3% compared with 11.9% on placebo, according to Psychiatric Times. Investigators stated that none of the serious adverse events were judged related to the study drug, attributing them instead to the underlying illness of a population that was already hospice-eligible.
That explanation may be reasonable, but it has not been tested against independent review, and the near-doubling of serious events is exactly the kind of signal that larger, independently reviewed trials exist to sort out. Until that happens, it remains the open question hanging over an otherwise positive efficacy result. A small Phase 2 trial, even a well-designed one, cannot distinguish reliably between a drug effect and a coincidence of illness severity. That distinction requires more participants, longer follow-up, and scrutiny from researchers who were not involved in running the original study.
What's Missing Before Any Conclusions Are Final
Everything publicly known about LiBBY so far comes from conference presentations and news summaries, not a peer-reviewed paper. No full publication of the trial's efficacy or safety data has appeared, which means the numbers above have not yet gone through the independent review that catches errors, confounders, or statistical issues before a result is accepted as reliable, as Being Patient's coverage of the trial noted. A twelve-week open-label extension phase — in which every participant, including those originally on placebo, received the active drug — has already been completed and was expected to be reported at AAIC 2026.
But no results from that extension, including its own safety data, had been published as of the most recent coverage. That phase matters because it's the first chance to see what happens when people stay on the drug longer, and whether the serious-adverse-event gap narrows, widens, or looks the same once everyone is exposed to it. No Phase 3 trial has been announced. A Phase 3 study would be larger, likely multi-site and more rigorously monitored, and is generally the step regulators expect before a drug reaches wider clinical use.
Does This Apply to Earlier-Stage Memory Concerns?
LiBBY's population was narrowly defined: adults with advanced dementia who were hospice-eligible and already experiencing significant agitation. The Georgetown University Medical Center release describing the trial is explicit that this group does not represent people with earlier-stage dementia or mild memory concerns.
That distinction matters because agitation, dosing tolerance, and risk of serious complications can look very different earlier in the disease course, when someone may still be living independently or managing mild cognitive symptoms. Nothing in the LiBBY results extends safety or benefit claims to that group. A caregiver or clinician looking at a family member with early memory loss is looking at a different clinical picture than the one this trial measured, and the data doesn't fill that gap.
- LiBBY's population: hospice-eligible, advanced dementia, significant agitation already present.
- Not covered by LiBBY: mild cognitive impairment, early-stage dementia, agitation that hasn't reached clinical significance.
What Caregivers and Clinicians Should Do Now
Given that the full data hasn't been published and the extension-phase safety results aren't out yet, the practical guidance circulating alongside the trial coverage is to wait. Commentary following the LiBBY results has advised clinicians and family caregivers to hold off on adopting THC/CBD combinations for dementia-related agitation outside of a clinical trial, pending published data and regulatory guidance on dosing, per commentary from CED Clinic.
That means there's no approved dosing standard, no FDA decision, and no indication yet for using a THC/CBD product like T2:C100 in routine dementia care. Anyone managing agitation in a family member with advanced dementia today is still working within existing, non-cannabinoid treatment options, and should raise questions about emerging research like LiBBY directly with the person's physician rather than treating topline conference results as a green light.
Frequently Asked Questions
Is the THC/CBD drug from the LiBBY trial approved for dementia agitation?
No. No Phase 3 trial has been announced, and only topline conference results and news summaries are available, not a peer-reviewed publication or regulatory approval.
Were the serious adverse events in LiBBY caused by the drug?
Investigators said none were judged related to the study drug, attributing them to the underlying illness in a hospice-eligible population, but that conclusion hasn't been confirmed by independent review.
Does LiBBY apply to people with early-stage dementia or mild memory loss?
No. The trial enrolled only hospice-eligible adults with advanced dementia and significant agitation, and its results don't establish safety or benefit for earlier-stage memory concerns.
You Might Also Like
- LiBBY Trial Findings for Late-Stage Dementia Agitation in 2026: What Researchers Still Need to Learn for Adults With Memory Concerns
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: What Researchers Still Need to Learn for Adults With Memory Concerns
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: What Researchers Still Need to Learn for Adults With Memory Concerns
